Palvella Therapeutics announces Qtorin docetaxel, a new Qtorin program for extramammary Paget’s disease
PVLA•Palvella Therapeutics announced Qtorin docetaxel, a new program to treat extramammary Paget’s disease. The company has initiated IND-enabling activities and plans a Phase 2 study.
1. New treatment program
Palvella Therapeutics announced Qtorin docetaxel as a new program for extramammary Paget’s disease. It has initiated IND-enabling activities and plans a Phase 2 study.




